Magazine Article | September 3, 2018

Novartis Turns To Digital Technologies For Clinical Trials

Source: Life Science Leader

By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical

New and innovative technologies are making their way into clinical trials. But which have the greatest potential to transform studies?

"We are currently seeing emerging digital technologies which have an incredible potential to unlock the next chapter of medical innovation,” says Jake LaPorte, head of digital development for Novartis. “Artificial intelligence (AI) and the Internet of Things (IoT) are two disruptive but complementary technologies that are beginning to find broad applications, not just in pharma but in all of our society. They’re likely to have profound effects on the underpinnings of our economy and our society more broadly, much as the internet has.”

VIEW THE MAGAZINE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader